


REGISTER BEFORE 20TH JULY AND
SAVE UP TO \$500!



SHANGHAI 2018 TUMOR MODELS

Improving IO and Oncology Outcomes from Preclinical to Translation

25th – 27th September, Pudong, Shanghai

tumor-models-shanghai.com

Improving IO and Oncology Outcomes from Preclinical and Translation

Expert speakers include:



Kerry Blanchard
CSO
**Innovent
Biologics**



Juan Liu
Head of External
Collaborations
Pfizer China



Hongtao Lu
CSO & Co-Founder
Elpiscience



Davy Ouyang
Senior Director
Crown Bioscience



Li Zhen
Executive Director,
Antibody Discovery
& Preclinical
Development
MABSPACE

Lead Partner



Hosting Partner



Welcome to the first Tumor Models Shanghai Conference

**Companies that
Attended Past Meetings
in the Series:**



Tumor Models Shanghai is the first of its kind to launch in Asia, following a successful 6-year history of delivering actionable insight to change the direction of research, we have held events in Boston, San Francisco and London.

By collaborating with key **thought leaders from Pharma, Biotech and Academia**, we have developed this agenda with the key challenges unique to the Asian landscape in mind.

As an industry-focused conference we strive to provide a platform where the sharing of ideas will give you the insight into how key thought leaders have advanced their pipelines from the preclinical and translation stage through to clinical success. Allowing you to take **practical, actionable information** away that will have a real world impact on your research.

To achieve this, we strongly encourage an open and frank discussion to change the way you think. A platform like this also aims to not only provide you with the **opportunity to learn and share ideas**, but to **find collaborations and build relationships** that are valuable to both your research and business goals.

Joining us will give you access to insight through various formats, including: **Talks, Panels, Roundtables and Workshops.**

“This conference was amazing! The collaborations I created are priceless. Thanks so much!”

Kiera Rycaj, Assistant Professor, Roswell Park Cancer Institute, Tumor Models Boston

The Key Insights You Will Hear About:

1.

How Crown Bioscience are **driving oncology discovery research** through implementation of their revolutionary Mouse Tumor Homograft Model Platform (MuPrime).



2.

Hear the way EpimAb leveraged information from throughout their preclinical phase to **better inform their clinical trial decisions** for their Bispecific Antibody EMB-01.



3.

How Innovent Biologics drove their pipeline forward using Humanized models in testing their **novel combination therapy**.



4.

Understand the thinking behind the **models selection process** behind the development of a therapeutic Antibody by Abxign.



5.

Hear about how YZY Biopharma used both **Syngeneic and PDX Models** in the development of their T-cell redirecting Bispecific Antibody.



EXPERT SPEAKERS



Junho Chung
CSO
Abxign



Bingliang Chen
Chief Scientist
Innovent Biologics



Kerry Blanchard
CSO
Innovent Biologics



Juan Liu
Head of External
Collaborations
Pfizer China



Pengfei Zhou
CEO
YZY Biopharma



Xuan Wu
Director of Biology
**EpimAb
Biotherapeutics**



Davy Ouyang
Senior Director
Crown Bioscience



James Keck
Senior Director In
Vivo Pharmacology
**The Jackson
Laboratory**



Lisa Ooi
Scientific Director
ASLAN Pharma



Paula Lam
Head, RnD
Stem Med Pte. Ltd



Hongtao Lu
CSO & Co-Founder
Elpiscience



Laura Benjamin
CSO & Co-Founder
**Oncologie
International**



James Yan
Executive VP,
Head Of Preclinical
Development & Drug
Safety
Zai Laboratory



Li Zhen
Executive Director,
Antibody Discovery
& Preclinical
Development
MABSPACE

“ Outstanding meeting with first class speakers. I learned a lot and I will certainly recommend the meeting to my colleagues ”

Tumor Model Series Attendee, Sanofi Aventis

PRE-CONFERENCE WORKSHOP

September 25th 2018

Guide to Utilising Humanized Mice for Your Immuno-Oncology Preclinical Research for Increased Translational Success

9:30am - 12:30pm

In this workshop you will find:

- Patient derived xenograft (PDX) mouse models recapitulate disease progression and respond to standard of care (SoC) and experimental therapies
- Specialized, immunodeficient mouse models are efficiently reconstituted with functional human immune cells
- Tumor-bearing, humanized NSG and NSG-SGM3 (Onco-Hu) mice are a new and valuable tool for Immuno-Oncology research.

Workshop Leader



James Keck
Senior Director In Vivo
Pharmacology
The Jackson Laboratory

“

This meeting is where industry and academic leaders brainstorm on how to improve our research and accelerate the development of safer and more effective I-O therapies

Shon Green, Preclinical Development, Eureka Therapeutics

”



“

Focused and concisely organized conference

Gerold Feuer, HuMurine Technologies, Tumor Models San Francisco

”



Conference Day One | 26th September 2018


	9.30 Chair's Opening Remarks
 Juan Liu Head of External Collaborations Pfizer China	9.40 Opening Talk: The State of Play for Preclinical Oncology Modelling in Asia - Take a look at the current challenges and opportunities that have come into play, and how they work in the context of China's biotech boom - What is going to happen over the next 12 months?
 Davy Ouyang Senior Director Crown Bioscience	10.10 Keynote Talk: Developing Mouse Tumor Homograft Model Platform (MuPrime) for Immuno-Oncology Drug Discovery - Immuno-oncology drug discovery, especially combinatory treatment, is now increasingly focused on targeting specific immune cell lineages to achieve synergistic effects - MuPrime models, derived from genetically engineered mouse spontaneous tumors, recapitulate human tumors both morphologically and at molecular levels, with clinical relevant oncogenic drivers - More importantly, MuPrime models offer a diverse spectrum of tumor microenvironment for testing different immunotherapeutic agents
	10.40 Speed Networking Bring lots of business cards for this highly interactive session. Introduce yourself to and network with many of the other attendees at the conference in a short space of time.
	11.30 Morning Refreshments
Models in Discovery and Exploration	
 Lisa Ooi Scientific Director ASLAN Pharma	12.00 In Vivo Modelling for Testing of a Novel Metabolic Pathway - Learn about the types of models used in exploration of a novel pathway - Understand how the results guide drug development
 James Keck Senior Director in vivo Pharmacology The Jackson Laboratory	12.30 Patient-Derived Tumor Xenografts in Humanized NSG-SGM3 Mice: A New Immuno-Oncology Platform - The addition of 3 human cytokines (GM-CSF, IL-3 & Kit Ligand) into the NSG mouse provide for a more robust myeloid compartment after humanization - Showcase data on the myeloid engraftment kinetics and also show checkpoint inhibitor efficacy against several PDX tumors
	1.00 Lunch
 Li Zhen Executive Director, Antibody Discovery & Preclinical Development MABSPACE	2.00 Preclinical Anti-Tumor Property of the 2nd Generation Anti-PDL1 MSB2311 - MSB2311 is differentiated by its distinct binding epitope and unique pH dependent PD-L1 binding and recycling property - The unique pH-dependent antigen binding property allows active antibody penetration and recycling in tumors, and leads to a much longer tumor residence time and has displayed excellent anti-tumor activities in multiple tumor models

Better Inform your Development Decisions with What You Learn from Preclinical Models

 Paula Lam Head, RnD Stem Med Pte. Ltd	2.30 Understanding the Biological Effects of Mesenchymal Stem Cells and their Effect on Different Tumor Microenvironments • Gain an insight to the role of mesenchymal stem cells in preclinical mouse models • Harness the potential of mesenchymal stem cells for anti-tumor properties
	3.00 Afternoon Refreshments

3.45 Roundtable Session: What are the Benefits and Limitations of the Mouse Models Currently Available?

The audience will be separated into groups in order to debate and rank in order of their level of impact on both Oncology and Immuno-Oncology Products. Gain new insights by hearing how others view the field and benefit from the shared collective experience of the delegation.



 Laura Benjamin CSO & Co-Founder Oncologie International	4.30 Using Data Gained from Preclinical Mouse Models to Better Inform Biomarker and Patient Selection • Learn about the models Oncologie are using to develop their novel therapies • Hear about the novel work Oncologie International are carrying out
	5.00 Chair's Closing Remarks
 The Jackson Laboratory	5.10 Networking Drinks • Relax and network after a hard day's learning at the conference. The drinks reception is provided by courtesy of The Jackson Laboratory

PART OF THE TUMOR MODELS EVENT SERIES


Conference Day Two | 27th September 2018

	9.30 Chair's Opening Remarks
 Kerry Blanchard CSO Innovent Biologics	9.35 Which Problem Should We Fix: The Targets, the Models or Both? - Understand why the quest for new drugs could be hampered by our models - Learn a new approach for the better use of models
 James Yan Executive VP, Head Of Pre-Clinical Development & Drug Safety Zai Laboratory	10.05 Hear About how Zai Labs are Driving their Diverse Pipeline Forward Details to be Confirmed
 Hongtau Lu CSO & Co-Founder Elpiscience  Kerry Blanchard CSO Innovent Biologics  Xuan Wu Director of Biology EpimAb Biotherapeutics	10.35 Panel Discussion: What is the Future of Immuno-oncology in Asia, in the Context of the Rapidly Changing Regulatory environment and Unique Biotech Landscape in Asia? - As Immuno-oncology research booms in Asia, what impact could this have on the preclinical field? - Do current models provide the tools needed to achieve clinical success? - What should we expect to change in the next 12 months?
	11.15 Morning Refreshments
Surmounting the Preclinical Development Hurdles for Novel Drug Modalities	
 Pengfei Zhou CEO YZY Biopharma	11.45 Case Study: Preclinical Development of T-Cell Redirecting Bispecific Antibodies - Get an overview of the key challenges faced when carrying out preclinical development of a T-Cell redirecting antibody - Learn how the PDX/Syngeneic models available can be used effectively to overcome these challenges - How to evaluate T cell induced cytokine storms in preclinical models
 Hongtao Lu CSO & Co-Founder Elpiscience	12.15 Challenge and opportunity in animal models for immuno-oncology - Learn the key considerations that need to be taken into account when using Humanized and Syngeneic - Hear how the Elpiscience have driven their pipeline forward through the effective use of available models
	12.45 Lunch & Networking
 Xuan Wu Director of Biology EpimAb Biotherapeutics	1.45 EMB-01: An Innovative cMet/EGFR Bispecific Antibody Targeting NSCLC - Introduction of EpimAb FIT-Ig® bispecific antibody platform - Introduction of EMB-01, an innovative cMet/EGFR bispecific antibody and its mechanism - How to leverage the preliminary in vivo efficacy study data to make decision for clinical study design

Overcoming Resistance Through Combination Therapies and Enhancing Sensitivity



Bingliang Chen
Chief Scientist
Innovent Biologics

2.15 **Case Study: TNFR-Superfamily Members OX40 Combination with anti-PD-1 in Humanized Mouse Model**

- Introduction to OX40 and its characteristics
- Gain insight into the screening of OX40 in vitro assays
- Efficacy of anti-OX40 plus anti-PD-1 in animal models specifically in the context of the humanized mouse model



Junho Chung
CSO
Abxign

2.45 **Preclinical Development of Anti-HGF (Hepatocyte Growth Factor) Antibody**

- Gain insight into the model selection process when developing a therapeutic antibody not reactive to mouse homologous antigen
- Re-visiting the mouse models for clinical development of therapeutic antibody

3.15 **Chair's Closing Remarks**


It's one of my favorite conferences. As a tumor modeler, it's wonderful to hear in one place what academics are doing, what industry values, and what problems are a challenge to all

Joshua Breunig, Cedars-Sinai/UCLA
Past delegate of Tumor Models San Francisco




Who will you meet?

WHERE OUR ATTENDEES COME FROM?*



*Based on market research including past events

WHAT OUR ATTENDEES DO?*



Pharma - 25%

Biotech - 32%

Research Institute - 20%

Service Providers - 20%

Other - 3%

*Based on market research including past events

PROUD TO PARTNER WITH



Lead Partner

Crown Bioscience. Our mission is to provide the “gold-standard” collection

of well characterised models and services for drug discovery to help our clients reduce the attrition rate of candidate compounds in the clinic, before they enter the clinic. Crown Bioscience, Inc. is a Preclinical CRO with expertise in the disease areas of Oncology and Metabolic Disease. We are known for the breadth and quality of our in vitro and in vivo models, as well as our ability to help clients quantify the real efficacy and pharmacological profile of their candidate before they move into the clinic.

www.crownbio.com



Hosting Partner

The Jackson Laboratory is a leading provider of cancer mouse models and in vivo

oncology services and a National Cancer Institute designated Cancer Center. Drawing on decades of research experience we provide capabilities around model selection, husbandry and customizable oncology studies to help clients and researchers evaluate novel anti-cancer therapies. Our diverse oncology study protocols range from traditional xenograft services to PDX cancer models and advanced humanized mouse models for Immuno-Oncology drug development.

www.jax.org

COMPANIES WHO HAVE ATTENDED PREVIOUS TUMOR MODELS EVENTS:



BECOME A PARTNER

Diane McKenna
Commercial Director, Tumor Models
T: +1 212 537 5898
E: sponsor@hansonwade.com



READY TO REGISTER?

- 1 Get the most up to date perspective on the novel features of Tumors
- 2 Find out how the thought leaders in the field are tackling these challenges and be involved in the discussion
- 3 See how this insight has Immuno-Oncology and Oncology examples of this knowledge being applied to change the way you can research

3 EASY WAYS TO BOOK

-  tumor-models-shanghai.com/take-part/register
-  Tel: +1 617 455 4188
-  Email: register@hansonwade.com

SECURE YOUR PLACE

INTERNATIONAL/ VENDOR PRICING	Register and Pay before 20th July 2018	Standard Prices
Conference + Workshop	\$2299 (save \$500)	\$2699 (save \$100)
Conference Only	\$1999 (save \$400)	\$2399
Workshop Only	\$399	

ACADEMIC/ASIAN DRUG DEVELOPER PRICING	Register and Pay before 20th July 2018	Standard Prices
Conference + Workshop	\$999 (save \$300)	\$1199 (save \$100)
Conference Only	\$799 (save \$200)	\$999
Workshop Only	\$299	

Team Discounts*

Make the most of the conference to collaborate with your team.

Special group discount bookings are available:

15% discount – 3 delegates

20% discount – 4 or more delegates

*Please note: Team discounts are only valid when three or more delegates from one company book and pay at the same time. 'Early Bird' discounts require payment at the time of registration (or prior to the cut-off date) to secure the applicable discount. All advertised discounts cannot be combined with any other offer. All bookings at this rate are subject to organizer final approval. T&Cs apply. Email info@hansonwade.com to inquire about the rate or apply.***



VENUE

Shanghai Intercontinental
 No.777 Zhangyang Road, Pudong New Area :
 Shanghai , SH ,200120, Mainland China
For further information or assistance, please visit
www.ihg.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time. Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers.

Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry.

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Team discounts cannot be applied to academic pricing

Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH